DE60330135D1 - Folatrezeptor gerichtete bildgebende Konjugate - Google Patents

Folatrezeptor gerichtete bildgebende Konjugate

Info

Publication number
DE60330135D1
DE60330135D1 DE60330135T DE60330135T DE60330135D1 DE 60330135 D1 DE60330135 D1 DE 60330135D1 DE 60330135 T DE60330135 T DE 60330135T DE 60330135 T DE60330135 T DE 60330135T DE 60330135 D1 DE60330135 D1 DE 60330135D1
Authority
DE
Germany
Prior art keywords
folate receptor
receptor directed
directed imaging
imaging conjugates
conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60330135T
Other languages
English (en)
Inventor
Christopher Paul Leamon
Matthew A Parker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endocyte Inc
Original Assignee
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc filed Critical Endocyte Inc
Application granted granted Critical
Publication of DE60330135D1 publication Critical patent/DE60330135D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/025—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus inorganic Tc complexes or compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
DE60330135T 2002-05-06 2003-05-06 Folatrezeptor gerichtete bildgebende Konjugate Expired - Lifetime DE60330135D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37857102P 2002-05-06 2002-05-06
PCT/US2003/014379 WO2003092742A1 (en) 2002-05-06 2003-05-06 Vitamin-targeted imaging agents

Publications (1)

Publication Number Publication Date
DE60330135D1 true DE60330135D1 (de) 2009-12-31

Family

ID=29401611

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60330135T Expired - Lifetime DE60330135D1 (de) 2002-05-06 2003-05-06 Folatrezeptor gerichtete bildgebende Konjugate

Country Status (19)

Country Link
US (5) US7128893B2 (de)
EP (4) EP2260875B1 (de)
JP (1) JP4801348B2 (de)
KR (1) KR100978418B1 (de)
CN (2) CN101648028B (de)
AT (1) ATE448799T1 (de)
AU (1) AU2003239383C1 (de)
CA (1) CA2484345C (de)
CY (1) CY1114733T1 (de)
DE (1) DE60330135D1 (de)
DK (3) DK2260875T3 (de)
ES (4) ES2336780T3 (de)
HK (1) HK1141440A1 (de)
IL (1) IL164811A (de)
NZ (1) NZ536467A (de)
PT (2) PT2151250E (de)
SI (2) SI2151250T1 (de)
WO (1) WO2003092742A1 (de)
ZA (1) ZA200408664B (de)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60231868D1 (de) 2001-04-24 2009-05-20 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
CA2445826C (en) 2001-05-02 2014-03-25 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
US8043603B2 (en) * 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8043602B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
PT2151250E (pt) 2002-05-06 2013-12-09 Endocyte Inc Agentes de formação de imagem direccionados para vitamina
AU2003243226A1 (en) * 2002-05-15 2003-12-02 Endocyte, Inc. Vitamin-mitomycin conjugates
EP2517730A3 (de) * 2003-01-27 2013-01-02 Endocyte, Inc. Vitaminrezeptorbindende Wirkstofffreisetzungskonjugate
US20060204565A1 (en) * 2003-05-06 2006-09-14 Low Philip S Conjugates and use thereof
WO2004110250A2 (en) 2003-05-30 2004-12-23 Purdue Research Foundation Diagnostic method for atherosclerosis
EP1789391B1 (de) 2004-07-23 2017-06-28 Endocyte, Inc. Zweiwertige linker und konjugate davon
EP1819716A4 (de) * 2004-11-10 2010-02-17 Univ South Florida Platinkomplexe zur gerichteten arzneimittelabgabe
CA2592302C (en) * 2004-12-23 2013-10-29 Purdue Research Foundation Positron emission tomography imaging method
JP5289935B2 (ja) * 2005-03-16 2013-09-11 エンドサイト，インコーポレイテッド プテロイン酸およびその結合体の合成と精製
US20070009434A1 (en) * 2005-07-05 2007-01-11 Low Philip S Imaging and therapeutic method using monocytes
US20080280937A1 (en) * 2005-08-19 2008-11-13 Christopher Paul Leamon Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives
RU2470668C2 (ru) * 2005-08-19 2012-12-27 Эндосайт, Инк. Конъюгаты лиганда с несколькими лекарственными средствами
WO2007038346A2 (en) 2005-09-23 2007-04-05 Purdue Research Foundation Multiphoton in vivo flow cytometry method and device
US8685752B2 (en) 2006-11-03 2014-04-01 Purdue Research Foundation Ex vivo flow cytometry method and device
EP2109466B1 (de) * 2007-02-07 2014-11-12 Purdue Research Foundation Positronenemissionstomografieverfahren
EP2609934A1 (de) 2007-02-16 2013-07-03 KTB Tumorforschungsgesellschaft mbH Rezeptor- und antigengerichtete Prodrug
WO2008101231A2 (en) * 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
CA2680535C (en) 2007-03-14 2016-09-20 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
CA2670385C (en) * 2007-04-11 2016-01-12 Merck Eprova Ag Folate-conjugates and corresponding metal-chelate complexes for use in diagnostic imaging and radiotherapy
WO2008125613A1 (en) 2007-04-11 2008-10-23 Merck Eprova Ag 18f-labelled folates
WO2008148001A2 (en) * 2007-05-25 2008-12-04 Purdue Research Foundation Method of imaging localized infections
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
WO2009002993A1 (en) 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
HUE047200T2 (hu) 2007-08-17 2020-04-28 Purdue Research Foundation PSMA kötõ ligandum-linker konjugátumok és azok alkalmazási módszerei
CN101909441B (zh) 2007-10-25 2015-05-13 恩多塞特公司 微管蛋白抑制剂及其制备方法
CN101903037A (zh) * 2007-11-15 2010-12-01 恩多塞特公司 施用偶合物的方法
US9332973B2 (en) 2008-10-01 2016-05-10 Covidien Lp Needle biopsy device with exchangeable needle and integrated needle protection
US9186128B2 (en) 2008-10-01 2015-11-17 Covidien Lp Needle biopsy device
US11298113B2 (en) 2008-10-01 2022-04-12 Covidien Lp Device for needle biopsy with integrated needle protection
US9782565B2 (en) 2008-10-01 2017-10-10 Covidien Lp Endoscopic ultrasound-guided biliary access system
US8968210B2 (en) 2008-10-01 2015-03-03 Covidien LLP Device for needle biopsy with integrated needle protection
US8426398B2 (en) 2009-01-13 2013-04-23 Emory University Conjugates of noscapine and folic acid and their use in treating cancer
EP2403863B1 (de) 2009-03-02 2013-08-28 Alnylam Pharmaceuticals Inc. Chemische modifikationen von nukleinsäure
EP2403412A4 (de) * 2009-03-05 2013-08-07 Purdue Research Foundation Verfahren zur frühen bildgebung von atherosklerose
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
PT2556171E (pt) 2010-04-05 2015-12-21 Prognosys Biosciences Inc Ensaios biológicos codificados espacialmente
US20190300945A1 (en) 2010-04-05 2019-10-03 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
WO2011130716A2 (en) 2010-04-16 2011-10-20 Access Pharmaceuticals, Inc. A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
US10913767B2 (en) 2010-04-22 2021-02-09 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
WO2011133868A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. Conformationally restricted dinucleotide monomers and oligonucleotides
WO2012122313A2 (en) 2011-03-08 2012-09-13 Access Pharmaceuticals, Inc. Targeted nanocarrier systems for delivery of actives across biological membranes
GB201106254D0 (en) 2011-04-13 2011-05-25 Frisen Jonas Method and product
AU2012296937B2 (en) 2011-08-17 2017-10-12 Merck & Cie Folate conjugates of albumin-binding entities
JP6228551B2 (ja) 2012-01-03 2017-11-08 インビクタス オンコロジー プライベート リミテッド リガンド−標的指向分子およびその方法
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
US9629918B2 (en) 2012-02-29 2017-04-25 Purdue Research Foundation Folate receptor alpha binding ligands
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
US20150174273A1 (en) * 2012-07-25 2015-06-25 Emory University Imaging and therapeutic methods for treating parathyroid tumors
EA201590622A1 (ru) 2012-10-16 2015-10-30 Эндосайт, Инк. Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения
KR101551232B1 (ko) 2012-10-26 2015-09-10 한국원자력연구원 Ｎ3ｓ1형의 새로운 킬레이터가 접합된 폴레이트 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암 진단 또는 치료용 조성물
JP6892218B2 (ja) 2012-11-15 2021-06-23 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 薬物送達結合体およびｐｓｍａ発現細胞によって引き起こされる疾患の治療方法
WO2014150943A1 (en) * 2013-03-15 2014-09-25 Purdue Research Foundation Asthma imaging and therapy
WO2014210223A1 (en) 2013-06-25 2014-12-31 Prognosys Biosciences, Inc. Spatially encoded biological assays using a microfluidic device
PE20160678A1 (es) 2013-10-18 2016-08-06 Deutsches Krebsforsch Inhibidores marcados de antigeno prostatico especifico de membrana (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata
EP3777898A3 (de) * 2013-11-14 2021-04-21 Endocyte, Inc. Verbindungen für positronenemissionstomografie
EP3574924B1 (de) 2013-11-19 2021-01-06 Purdue Research Foundation Patientenauswahlverfahren für entzündungen
CA2944401A1 (en) 2014-04-03 2015-10-08 Invictus Oncology Pvt. Ltd. Supramolecular combinatorial therapeutics
EP3160514A4 (de) * 2014-06-27 2018-02-28 Reiley Pharmaceuticals, Inc. Konjugate aus nichtsteroidalen entzündungshemmern und verfahren zur verwendung davon in der bildgebung
US20160166679A1 (en) * 2014-12-12 2016-06-16 Purdue Research Foundation Method of treatment using folate conjugates and tyrosine kinase inhibitors
CA2970795A1 (en) 2014-12-18 2016-06-23 Alnylam Pharmaceuticals, Inc. Reversir compounds
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
US10053478B2 (en) 2015-01-09 2018-08-21 Reiley Pharmaceuticals, Inc. COX-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers
CN107532207B (zh) 2015-04-10 2021-05-07 空间转录公司 生物样本的空间区别、多重核酸分析
US11053495B2 (en) 2015-07-17 2021-07-06 Alnylam Pharmaceuticals, Inc. Multi-targeted single entity conjugates
ES2811347T3 (es) 2015-08-14 2021-03-11 Endocyte Inc Método de formación de imágenes con un compuesto quelante
SG11201804086VA (en) 2015-12-04 2018-06-28 10X Genomics Inc Methods and compositions for nucleic acid analysis
AU2017234676A1 (en) 2016-03-16 2018-09-20 Purdue Research Foundation Carbonic anhydrase IX targeting agents and methods
US10857234B2 (en) 2016-03-16 2020-12-08 Endocyte Inc. Carbonic anhydrase IX inhibitor conjugates and uses thereof
US20170296679A1 (en) 2016-04-18 2017-10-19 Intuitive Surgical Operations, Inc. Compositions of Near IR Closed Chain, Sulfo-Cyanine Dyes and Prostate Specific Membrane Antigen Ligands
US11524082B2 (en) 2017-08-22 2022-12-13 Purdue Research Foundation FBSA-based therapeutic and radioimaging conjugates targeting carbonic anhydrase positive cancers
MX2020011570A (es) 2018-05-07 2020-11-24 Alnylam Pharmaceuticals Inc Administracion extrahepatica.
TW202028465A (zh) 2018-09-28 2020-08-01 美商阿尼拉製藥公司 甲狀腺素運載蛋白（ＴＴＲ）ｉＲＮＡ組成物及其治療或預防ＴＴＲ相關眼部疾病之使用方法
CA3138915A1 (en) 2019-05-17 2020-11-26 Alnylam Pharmaceuticals, Inc. Oral delivery of oligonucleotides
WO2021086982A2 (en) 2019-10-28 2021-05-06 Beckman Coulter, Inc. Compounds for the identification of microbial classes and uses thereof
KR20220110749A (ko) 2019-11-06 2022-08-09 알닐람 파마슈티칼스 인코포레이티드 간외 전달
WO2021092145A1 (en) 2019-11-06 2021-05-14 Alnylam Pharmaceuticals, Inc. Transthyretin (ttr) irna composition and methods of use thereof for treating or preventing ttr-associated ocular diseases
WO2021252499A1 (en) 2020-06-08 2021-12-16 10X Genomics, Inc. Methods of determining a surgical margin and methods of use thereof
US20230257745A1 (en) 2020-07-10 2023-08-17 Alnylam Pharmaceuticals, Inc. Circular siRNAs
EP4237087A1 (de) 2020-10-30 2023-09-06 Speer, Tod Therapeutika auf oligonukleotidbasis und verwendungen davon
WO2022147214A2 (en) 2020-12-31 2022-07-07 Alnylam Pharmaceuticals, Inc. Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
WO2022147223A2 (en) 2020-12-31 2022-07-07 Alnylam Pharmaceuticals, Inc. 2'-modified nucleoside based oligonucleotide prodrugs
WO2022150721A1 (en) * 2021-01-08 2022-07-14 Lycia Therapeutics, Inc. Bifunctional folate receptor binding compounds
WO2023283403A2 (en) 2021-07-09 2023-01-12 Alnylam Pharmaceuticals, Inc. Bis-rnai compounds for cns delivery
KR20240036041A (ko) 2021-07-21 2024-03-19 알닐람 파마슈티칼스 인코포레이티드 대사 장애-연관 표적 유전자 iRNA 조성물 및 이의 사용 방법
WO2023064530A1 (en) 2021-10-15 2023-04-20 Alnylam Pharmaceuticals, Inc. Extra-hepatic delivery irna compositions and methods of use thereof
WO2023220744A2 (en) 2022-05-13 2023-11-16 Alnylam Pharmaceuticals, Inc. Single-stranded loop oligonucleotides
WO2024006999A2 (en) 2022-06-30 2024-01-04 Alnylam Pharmaceuticals, Inc. Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
WO2024073732A1 (en) 2022-09-30 2024-04-04 Alnylam Pharmaceuticals, Inc. Modified double-stranded rna agents

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2816110A (en) * 1956-11-23 1957-12-10 Merck & Co Inc Methods for the production of substituted pteridines
US5140104A (en) * 1982-03-09 1992-08-18 Cytogen Corporation Amine derivatives of folic acid analogs
US5175343A (en) * 1985-01-14 1992-12-29 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5242679A (en) * 1985-01-14 1993-09-07 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
NZ217821A (en) 1985-10-10 1989-07-27 Biotech Australia Pty Ltd Oral delivery system; complex of active agent and vitamin b12 or analogue thereof
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
EP0273085A1 (de) 1986-12-29 1988-07-06 IntraCel Corporation Verfahren zur Einführung fremder Nukleinsäuren in eukaryotische Zellen
US5053493A (en) * 1987-04-02 1991-10-01 Centocor Cardiovascular Imaging Partners, L.P. Method for labeling antibodies with a metal ion
US5688488A (en) * 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
US7238340B1 (en) * 1991-11-27 2007-07-03 Cis Bio International Monoamine, diamide, thiol-containing metal chelating agents
ES2141102T3 (es) * 1991-02-08 2000-03-16 Diatide Inc Polipeptidos marcados con tecnecio-99m para la generacion de imagenes.
US6335434B1 (en) * 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
US5159079A (en) * 1991-12-20 1992-10-27 Eli Lilly And Company 2-piperidones as intermediates for 5-deaza-10-oxo- and 5-deaza-10-thio-5,6,7,8-tetrahydrofolic acids
US6022966A (en) 1993-11-22 2000-02-08 Neorx Corporation Pretargeting methods and compounds
DE4311021A1 (de) * 1993-03-31 1994-10-27 Diagnostikforschung Inst Bifunktionelle Chelatbildner, deren Technetium- und Rhenium-Komplexe, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende radiopharmazeutische Mittel
DE4310999C2 (de) * 1993-03-31 1996-07-18 Diagnostikforschung Inst Bifunktionelle chalkogenatom-unterbrochene Chelatbildner vom Typ XN¶1¶S¶1¶X' für radioaktive Isotope und deren Metallkomplexe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Mittel
DE4311022C2 (de) * 1993-03-31 1996-07-11 Diagnostikforschung Inst Bifunktionelle chalkogenatom-unterbrochene Chelatbildner vom Typ S¶3¶N¶2¶ für radioaktive Isotope und deren Metallkomplexe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Mittel
DE4311023C2 (de) * 1993-03-31 1996-05-02 Diagnostikforschung Inst Bifunktionelle chalkogenatom-unterbrochene Chelatbildner von Typ XN¶1¶S¶1¶O¶1¶ für radioaktive Isotope, deren Metallkomplexe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Mittel
DE4425781A1 (de) * 1994-07-14 1996-01-18 Schering Ag Technetium-Sulfonamid-Komplexe, deren Verwendung, diese enthaltende pharmazeutische Mittel, sowie Verfahren zur Herstellung der Komplexe und Mittel
US6083480A (en) * 1997-05-01 2000-07-04 Diatide, Inc. Calcitonin receptor binding reagents
US6093382A (en) * 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
US6323313B1 (en) * 1999-06-01 2001-11-27 The University Of Washington Annexin derivative with endogenous chelation sites
CA2410906C (en) * 2000-06-02 2012-10-02 Board Of Regents, The University Of Texas System Ethylenedicysteine (ec)-drug conjugates
CA2445826C (en) * 2001-05-02 2014-03-25 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
PT2151250E (pt) 2002-05-06 2013-12-09 Endocyte Inc Agentes de formação de imagem direccionados para vitamina
EP2517730A3 (de) * 2003-01-27 2013-01-02 Endocyte, Inc. Vitaminrezeptorbindende Wirkstofffreisetzungskonjugate
US20060204565A1 (en) * 2003-05-06 2006-09-14 Low Philip S Conjugates and use thereof

Also Published As

Publication number Publication date
WO2003092742A1 (en) 2003-11-13
JP2006501149A (ja) 2006-01-12
CN101648028A (zh) 2010-02-17
SI2260875T1 (sl) 2014-07-31
AU2003239383C1 (en) 2009-03-19
US20130237687A1 (en) 2013-09-12
JP4801786B2 (ja) 2011-10-26
ZA200408664B (en) 2007-04-25
CN1662263A (zh) 2005-08-31
PT2151250E (pt) 2013-12-09
PT2260875E (pt) 2014-06-25
EP1501551B1 (de) 2009-11-18
US7128893B2 (en) 2006-10-31
ES2438008T3 (es) 2014-01-15
CA2484345A1 (en) 2003-11-13
AU2003239383A1 (en) 2003-11-17
EP2260875A2 (de) 2010-12-15
EP2258401B1 (de) 2014-07-09
DK2151250T3 (da) 2013-12-16
KR20040104686A (ko) 2004-12-10
EP2151250A1 (de) 2010-02-10
ES2500922T3 (es) 2014-10-01
ATE448799T1 (de) 2009-12-15
ES2472423T3 (es) 2014-07-01
AU2003239383B2 (en) 2008-10-16
EP2151250B1 (de) 2013-10-02
CY1114733T1 (el) 2016-12-14
CN101648028B (zh) 2012-11-21
US7862798B2 (en) 2011-01-04
NZ536467A (en) 2006-11-30
US20040033195A1 (en) 2004-02-19
CN100528241C (zh) 2009-08-19
EP1501551A4 (de) 2006-01-11
ES2336780T3 (es) 2010-04-16
KR100978418B1 (ko) 2010-08-26
US20090324499A1 (en) 2009-12-31
US20070031334A1 (en) 2007-02-08
DK2260875T3 (da) 2014-06-30
US8313728B2 (en) 2012-11-20
IL164811A (en) 2012-06-28
DK2258401T3 (da) 2014-10-13
CA2484345C (en) 2015-09-29
US8865126B2 (en) 2014-10-21
US8834842B2 (en) 2014-09-16
EP1501551A1 (de) 2005-02-02
EP2258401A2 (de) 2010-12-08
HK1141440A1 (en) 2010-11-12
EP2260875A3 (de) 2011-08-24
EP2258401A3 (de) 2011-08-24
US20140065068A1 (en) 2014-03-06
SI2151250T1 (sl) 2014-02-28
JP4801348B2 (ja) 2011-10-26
JP2011012066A (ja) 2011-01-20
EP2260875B1 (de) 2014-04-23

Similar Documents

Publication Publication Date Title
DE60330135D1 (de) Folatrezeptor gerichtete bildgebende Konjugate
LTPA2017036I1 (lt) Kalicheamicino darinio-nešiklio konjugatai
CY1113054T1 (el) Παραγωγα διαμινης
DE60230163D1 (de) Sicherheitsgurt-vorspannvorrichtung
DE60110844D1 (de) Chinazolone derivate als alfa 1a/b adrenozeptor antagonisten
CY1114008T1 (el) Θειενοπυριμιδινικες ενωσεις και χρηση τους
CY1105705T1 (el) Παραγωγα ινδολυλαλκυλαμινης σαν συνδετηρες 5-υδροξυτρυπταμινης-6
NO20034068L (no) Fleksibel forbindelse for brönnloggingsinstrumenter
ATE413175T1 (de) Spiroinden- und spiroindan-verbindungen
ATE302775T1 (de) Carbolinderivate
DE60215179D1 (de) Dolastatin 10 derivate
ATE346067T1 (de) Carbolinderivate
NO20010100L (no) Beltestyreenhet
DE60237109D1 (de) Rbesserte transistoreigenschaften
DE502004000410D1 (de) Gurtstraffer bei einer höhenverstellbaren Gurtumlenkeinrichtung
EE200300480A (et) Pregabaliini-laktoosi konjugaadid
SV2003000981A (es) Fenil-heterociclil-eteres ref. pcs10973
NO20032577D0 (no) Söm for korrugert belte
DE60211116D1 (de) Ausgleichsmechanismus
DE50200900D1 (de) Fixiereinrichtung
DE60215804D1 (de) 4-aminopyrimidine derivate
DE60039695D1 (de) Antifucoidan antikörper
SE0202617L (sv) Lysande spännbandssträckare
ATE377608T1 (de) Hemoglobin konjugate
FR2829754B1 (fr) Bobinoir transformable sur site

Legal Events

Date Code Title Description
8364 No opposition during term of opposition